Ophthalmic Business News

Verséa Ophthalmics announced the distribution of its T-POC Total IgE Immunoassay Kit, a tear-based point-of-care test for the diagnosis and management of ocular surface disease.

The FDA approved Xdemvy, a 0.25% lotilaner ophthalmic solution, for the treatment of Demodex blepharitis, according to a press release from Tarsus Pharmaceuticals.

The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended approval of Yesafili, an aflibercept biosimilar, according to a press release from Biocon Biologics.

Harrow announced that it signed agreements with Santen Pharmaceutical Co. affiliates to acquire their branded ophthalmic portfolio and also with Novaliq GmbH to acquire Vevye.

Visiox Pharma has entered into a definitive agreement with Santen Pharmaceutical to license product manufacturing and commercialization rights for Omlonti in the U.S., according to a press release.

Caeregen Therapeutics has been awarded a $1.4 million phase 2 Small Business Innovation Research grant for the development of CTR-107 for the treatment of retinal-related vision loss due to inherited and age-related diseases.

OcuTerra Therapeutics completed enrollment in the phase 2 DR:EAM clinical trial, which is investigating OTT166 eye drops for the treatment of diabetic retinopathy, according to a press release.

Laura B. Enyedi, MD, and Dagny Zhu, MD, discuss contract negotiations and the gender wage-gap in ophthalmology with Lisa Nijm, MD, JD.

Concerns about potential malpractice liability are top of mind for many physicians of all specialties. This is not surprising given recent verdicts in medical malpractice actions that have awarded millions of dollars in damages to plaintiffs.

Tenpoint Therapeutics has launched with a $70 million Series A financing, which will be used to develop regenerative medicine platforms to replace cells destroyed by inherited and age-related ocular diseases, according to a press release.